These targets include tumor-infiltrating lymphocytes (TILs), programmed death ligand protein-1 (PD-L1) expression levels, tumor mutational burden (TMB), microsatellite instability (MSI), IFN γ signature, B cell infiltration, as well as liquid biopsy markers like circulating tumor cells (CTCs) and cell-free DNA (cfDNA) (116–122). Here, CD274 is linked to neoplasm.